Aspira Pathlab Stock: price and insider trades · India
1 insider bought €3,485 of shares over the last 90 days, the latest by Jay Arvind Bhanushali, filed 01 Oct 2026.
Aspira Pathlab: what insiders have been doing
This page follows insider dealings at Aspira Pathlab as filed with SEBI (PIT + SAST). Over the twelve months to 10 November 2026, 11 filings were filed, from 6 insiders.
Every open-market trade in the period is a purchase: 6 purchases worth €3,485, from 1 insider, and not a single sale. The totals do not cover 1 filing with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Biggest ticket of the year: €1,650, bought by Jay Arvind Bhanushali and made public on 29 September 2026 (0.013% of market cap). Those buying include 1 major shareholder.
For context, the typical company on the same exchange (median of 1,987 companies) published 4 filings over the same period, against 11 filings here. Our records for Aspira Pathlab go back to 2026, with 6 purchases and no sales on the open market in total.
The last purchase on record was published on 1 October 2026, which is 40 days ago. Publication is fast: at least half of the trades appear on SEBI (PIT + SAST) on the same day. This delay matters because a trade only becomes useful information once it is public.
Every figure here comes from the filings published by SEBI (PIT + SAST) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- +50.0%Entry ₹90.00 · Close at T+30 ₹135.02
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
- 245 shares@ ₹130.000.0022% mcap8.4% of flowEquityMarket PurchaseSEBI:54b384e03dd3e0994f86ccf46b389af42eb871d3Canonical exit: 30 Dec 2026 (T+90)
- 1,424 shares@ ₹126.300.013% mcap51.7% of flowEquityMarket PurchaseSEBI:6061f988bf986cd36d3c23e68028e85378cc6d8bCanonical exit: 28 Dec 2026 (T+90)
- 332 shares-MarketSEBI:a7ebccd315f26cc8e302ed3b9aa2f2f5abca0621Canonical exit: 22 Dec 2026 (T+90)
- 1,387 shares@ ₹96.900.010% mcap79.2% of flowEquityMarket PurchaseSEBI:10f2e536a4c8219bcb48cacf3c09181981a824c1Canonical exit: 16 Dec 2026 (T+90)
- 74 shares@ ₹94.600.0005% mcap4.1% of flowEquityMarket PurchaseSEBI:b85393707b4632e352d868767cd402ebe32d48f1Canonical exit: 11 Dec 2026 (T+90)
- 332 shares@ ₹86.500.0021% mcap16.7% of flowEquityMarket PurchaseSEBI:e0586f9c9544fe48a33f759bf3a29cdf5f6a9adfCanonical exit: 26 Nov 2026 (T+90)
- 2,282,507 shares-Open OfferSEBI:4cb6543a1b714ea2f1fe0d93b159190823f37003
- 2,282,507 shares-Open OfferSEBI:8c6ca2c45cd85299ee017d7be0bc13f36c20341a
- 2,282,507 shares-Open OfferSEBI:043c04c5cf12f3a4657081ddfecfbb0ff8fed455
- 2,282,507 shares-Open OfferSEBI:4ebccedcd6bf38177fe6ab9cfbec33aac8f93328
- 2,282,507 shares-Open OfferSEBI:fb5c3e20be2e4cb5925d91459cb27b5ad5b18de9
11 of 11 declarations
About Aspira Pathlab
Aspira Pathlab is a company specializing in medical diagnostic services, providing laboratory analysis and health testing. It operates in the XBOM market.